A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibManagement of polycythaemia vera: a critical review of current data.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Safety evaluation of ruxolitinib for treating myelofibrosis.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.Ruxolitinib: A Review in Polycythaemia Vera.Experience with ruxolitinib in the treatment of polycythaemia vera.Polycythemia Vera Management and Challenges in the Community Health Setting.Pharmacological management of essential thrombocythemia.The European LeukemiaNet: achievements and perspectives.Current and future treatment options for polycythemia vera.Emerging treatments for essential thrombocythemiaDiagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary RoundtableNovel and emerging therapies for the treatment of polycythemia veraPhiladelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.Emerging drugs for polycythemia vera.Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groupsTherapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias].Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.Ruxolitinib for the treatment of patients with polycythemia vera.Advances and challenges in the management of essential thrombocythemia.JAK2 inhibitors for myeloproliferative neoplasms: what is next?Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy.Primary myelofibrosis: current therapeutic options.Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.Developmental Therapeutics in Myeloproliferative Neoplasms.Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
P2860
Q26750696-3C9EAC39-76A6-4043-A19D-240D21BFA244Q31009757-62BC2241-01EB-4B70-9020-EE536838E8B2Q33411637-55F4E050-80EA-4DBC-82C6-17F319E89E68Q33415731-4D5AA036-21E1-48C3-8F74-3366D5F0F77EQ33420037-0818E554-FFC1-4FA1-A5E3-89A780FC1171Q33425781-1B6F92EC-2FE8-46DF-92EC-EE52E75D0525Q33605624-0C2A28D8-A12A-4735-AF00-564C05AD139DQ33803036-2BE98202-3DDC-499E-B8BF-388E04D0B7DCQ34344384-23C083D6-1D34-47AF-B441-291F38EA4CEBQ34451619-74A237CF-1EAF-4D60-BB19-B51E52139CB3Q35572748-B1A34AED-4D1D-4FE3-B6CD-076FFE7F3D63Q35683853-4D408477-4C9B-4471-82FD-33EC3C54C644Q36266377-0DF985EA-7FFF-409D-8BD8-9D32D7FFF643Q37069633-A2FD403D-32B8-464A-B6B3-3E3683945D58Q37163590-B041B41B-31E9-499B-9997-F12A2BA12B21Q37555790-A07AAC23-045A-485F-9CFB-FA759D154033Q38014534-22869B8A-B48F-43B3-A76C-1E7E438702CBQ38130749-CEF41BA5-26C7-41AA-B1B5-EA136D8FEF85Q38134374-A62D3262-30A3-4C94-9B0A-ADE2DB748B82Q38187684-4A4F3908-351D-4F93-A16B-A3002360561DQ38255717-ACF1DCDE-25C0-4344-894B-5757F9C51000Q38292400-34C79B47-B688-4EFA-979B-64B05D77EC07Q38382105-633F3864-B597-4F0A-B9FA-1343B6807791Q38393343-73F59998-CDB0-4424-8647-994BFB2D5B83Q38420817-632E45F6-32D5-40BC-9BDA-ED2963DF1E69Q38484321-5FDADA95-B1DC-46E3-8CC9-6EB2F762CAE1Q38542093-117E4D4E-62A6-48AC-801A-90A6C950D1A4Q38684435-BDE1310B-91C8-4C42-963B-4960361988C2Q38723484-C63A8513-5765-4D84-86EE-17B3483CE857Q38740700-C1C89097-FA5C-4B9D-9571-D6F38DBFC22DQ38840350-AA8A7E61-6E87-4EB9-A631-29FEF901ABE8Q38984578-5ABBFD2D-3533-4A4F-BFD8-AD266224DCDFQ39563439-310AD531-A398-422F-A2E9-2AA47F25D229Q40560173-BDCA3A76-D499-4972-B94A-EB9ABEEED4BFQ41095829-9DD66079-4991-4665-8353-72CD3861044EQ41186952-E98E26D1-5BB3-4C8D-83EC-DDA6298364B9Q43731510-28A8CA78-86D7-4AC3-B864-CB79D03568BDQ45994535-8A1BB364-C339-4E93-B9F8-50FBCDC8B05EQ48008083-4DD01992-698B-4BD2-BC02-AA53EC58A712Q48226545-18E79559-651D-44DC-9C53-1AC8B721F09B
P2860
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A unified definition of clinic ...... iaNet (ELN) consensus process.
@en
A unified definition of clinic ...... ults of a European LeukemiaNet
@nl
type
label
A unified definition of clinic ...... iaNet (ELN) consensus process.
@en
A unified definition of clinic ...... ults of a European LeukemiaNet
@nl
prefLabel
A unified definition of clinic ...... iaNet (ELN) consensus process.
@en
A unified definition of clinic ...... ults of a European LeukemiaNet
@nl
P2093
P1476
A unified definition of clinic ...... iaNet (ELN) consensus process.
@en
P2093
Alessandro M Vannucchi
Claire Harrison
Eva Lengfelder
Giovanni Barosi
Guido Finazzi
Gunnar Birgegard
Jean-Jacques Kiladijan
John T Reilly
Martin Griesshammer
Mary F Mc Mullin
P304
P356
10.1111/J.1365-2141.2009.08019.X
P407
P577
2009-11-23T00:00:00Z